Insider Selling: Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Sells $171,532.08 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) EVP Craig E. Hunsaker sold 13,878 shares of the stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $12.36, for a total value of $171,532.08. Following the transaction, the executive vice president now owns 1,450,018 shares of the company’s stock, valued at approximately $17,922,222.48. The trade was a 0.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Alphatec Stock Up 2.3%

NASDAQ ATEC opened at $12.73 on Monday. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $13.14. The stock has a market capitalization of $1.86 billion, a PE ratio of -9.95 and a beta of 1.10. The business has a fifty day moving average price of $11.52 and a two-hundred day moving average price of $10.77.

Alphatec (NASDAQ:ATEC) last issued its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.23). The company had revenue of $169.18 million during the quarter, compared to analyst estimates of $167.57 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. The business’s quarterly revenue was up 22.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.34) EPS. Equities analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ATEC shares. Wall Street Zen upgraded shares of Alphatec from a “sell” rating to a “hold” rating in a research note on Friday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Alphatec in a report on Monday, April 14th. Needham & Company LLC restated a “buy” rating and set a $16.00 price objective on shares of Alphatec in a report on Friday, May 2nd. Finally, Piper Sandler restated an “overweight” rating and issued a $15.00 price target (up from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $17.89.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Nuveen LLC acquired a new stake in shares of Alphatec in the first quarter valued at about $135,874,000. Vanguard Group Inc. grew its stake in shares of Alphatec by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company’s stock valued at $60,990,000 after buying an additional 45,792 shares during the period. American Century Companies Inc. increased its holdings in shares of Alphatec by 16.9% during the first quarter. American Century Companies Inc. now owns 5,830,031 shares of the medical technology company’s stock valued at $59,117,000 after acquiring an additional 840,974 shares in the last quarter. Royal Bank of Canada increased its stake in Alphatec by 10.8% during the 1st quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company’s stock valued at $35,773,000 after purchasing an additional 342,656 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its holdings in shares of Alphatec by 78.4% in the 4th quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company’s stock worth $23,730,000 after acquiring an additional 1,136,330 shares during the last quarter. Institutional investors and hedge funds own 66.35% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.